// App-Quantinova.ai

1115 : T-DXd increases immune cell infiltration and enhances activity of immune checkpoint blockade in murine tumor models

Researchers

Presenter

  • Liam Jenkins

Principal Investigators

  • Matt Wilson

  • Jerome Mettetal

  • Theresa Proia

Medical Centers

  • AstraZeneca UK Ltd, Cambridge, UK

  • AstraZeneca Pharmaceuticals, Waltham, MA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 2AP

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • monomethyl auristatin E

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved